SPZ1

Across TCGA pan-cancer cohorts, SPZ1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPZ1 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SPZ1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPZ1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LGG show a favorable association.

KICH, UCEC, and TGCT are the cancer types where SPZ1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.922	0.437	.027	10	view →
TGCT	DFS	Median	All	0.040	0.837	<.001	6	view →
SKCM	DFS	Median	III,IV	0.188	0.548	.045	4	view →
LGG	OS	Median	All	1.000	0.413	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPZ1–KICH (DFS)

Open the KICH breakdown →